Drugs / GSK3008348
GSK3008348
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03069989 | Jun 2017 → Jul 2018 | idiopathic pulmonary fibrosis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1 | NCT02612051 | Dec 2015 → Jun 2016 | idiopathic pulmonary fibrosis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK3008348 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02612051 ↗ |
| Known as | Gsk3008348 monohydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL4241824 ↗ |
| Known as | Gsk3008348e | ChEMBL registry synonym — accepted as the source's own label CHEMBL4241824 ↗ |
| Modality | Small molecule | — CHEMBL4241824 ↗ |
| Route | Other | “single nebulized doses of 1-3000 micrograms (mcg) GSK3008348” NCT03069989 ↗ |